Our results that SLC25A21 downregulation increased GTP production and KRAS activity and subsequently activated the PI3K/AKT and RAF/ERK signaling pathways encouraged us to explore the effect of SLC25A21 dysregulation on the efficacy of anti-EGFR antibody treatment in KRAS-mutant CRC. The gene discussed is SLC25A21; the disease is colorectal carcinoma.